---
title: "Pharmaron Beijing Co., Ltd. (300759.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300759.SZ.md"
symbol: "300759.SZ"
name: "Pharmaron Beijing Co., Ltd."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-20T11:52:25.315Z"
locales:
  - [en](https://longbridge.com/en/quote/300759.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300759.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300759.SZ.md)
---

# Pharmaron Beijing Co., Ltd. (300759.SZ)

## Company Overview

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | CN Market |
| Website | [www.pharmaron.cn](https://www.pharmaron.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: B (0.35)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 2 / 26 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 14.73% |  |
| Net Profit YoY | -9.35% |  |
| P/B Ratio | 2.94 |  |
| Dividend Ratio | 0.73% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 48461724010.31 |  |
| Revenue | 14600613647.70 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 11.11% | B |
| Profit Margin | 11.62% | B |
| Gross Margin | 32.50% | C |
| Revenue YoY | 14.73% | B |
| Net Profit YoY | -9.35% | D |
| Total Assets YoY | 17.38% | A |
| Net Assets YoY | 16.85% | B |
| Cash Flow Margin | 175.51% | B |
| OCF YoY | 14.73% | B |
| Turnover | 0.55 | C |
| Gearing Ratio | 40.08% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Pharmaron Beijing Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "14.73%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-9.35%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.94",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.73%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "48461724010.31",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "14600613647.70",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "11.11%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "11.62%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "32.50%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "14.73%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-9.35%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "17.38%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "16.85%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "175.51%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "14.73%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.55",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "40.08%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 28.56 | 2/26 | 38.17 | 34.04 | 28.02 |
| PB | 2.94 | 10/26 | 3.90 | 3.67 | 3.27 |
| PS (TTM) | 3.32 | 4/26 | 4.22 | 3.96 | 3.56 |
| Dividend Yield | 0.73% | 5/26 | 0.73% | 0.66% | 0.63% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | WuXi AppTec (603259.SH) | A | A | C | A | B | B |
| 02 | Pharmaron (300759.SZ) | B | B | C | B | B | B |
| 03 | Chemexpress (688131.SH) | B | B | C | C | B | B |
| 04 | HitGen (688222.SH) | B | A | D | B | C | B |
| 05 | GEMPHARMATECH (688046.SH) | B | B | D | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-06T16:00:00.000Z

Total Analysts: **15**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 53% |
| Overweight | 3 | 20% |
| Hold | 2 | 13% |
| Underweight | 1 | 7% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 26.67 |
| Highest Target | 40.30 |
| Lowest Target | 23.80 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300759.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300759.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300759.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300759.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**